-
1 month ago | 
onlinelibrary.wiley.com | Raffi Tachdjian |Aleena Banerji |Paula J. Busse |Nancy Agmon-Levin
There is currently a shortage of data on long-term prophylaxis outcomes in adolescents with hereditary angioedema (HAE). In this study, we employed pooled data from 2 real-world observational studies to assess the effectiveness and safety of lanadelumab in preventing HAE attacks in patients aged 12–17 years with HAE-C1INH.
-
Oct 1, 2024 | 
onlinelibrary.wiley.com | Petra Staubach |Raffi Tachdjian |Los Angeles USA |H. Li
Garadacimab provided consistent HAE attack prevention in manufacturer-funded post hoc pivotal Phase 3 data analysis. Protection from HAE attacks occurred by Week 1 after first administration.
-
Jul 26, 2023 | 
hcplive.com | Raffi Tachdjian |Dareen Siri |Nicole Chase
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: We could see we’re no longer driving cars—we’re flying airplanes when it comes to treating severe asthma. More intricate, and certainly requires more training and more experience, as we said earlier. I wanted to thank each and every one of you for this rich and informative exchange and discussion. And I wanted to give you each a few more minutes to summarize your thoughts. I’ll start with you, Dr Chase. Do you have any last thoughts or last words?
-
Jul 26, 2023 | 
hcplive.com | Raffi Tachdjian |Dareen Siri |Nicole Chase |Andrew White
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: We talked about biomarkers to start this conversation and segment, to qualify the level of severity of asthma. And we’re going to wind down now and come full circle. Dr Siri, what is the role of biomarkers as you progress prognostically and follow your patients who are on biologics? Dareen D. Siri, MD, FAAAAI, FACAAI: Thank you for asking me that because we’ve all been throwing out the word biomarkers without actually really defining them.
-
Jul 26, 2023 | 
hcplive.com | Raffi Tachdjian |Dareen Siri |Nicole Chase |Andrew White
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: Let’s switch gears to barriers in the use of biologics in clinical practice. Dr White, do you see any trends or utilization differences, with the penetration of therapeutics, into the lives of patients with severe asthma, moderate to severe asthma, eosinophilic asthma, and difficult-to-treat asthma, among primary care providers or physicians vs the specialists?
-
Jul 26, 2023 | 
patientcareonline.com | Raffi Tachdjian |Dareen Siri |Nicole Chase |Andrew White
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: We could see we’re no longer driving cars—we’re flying airplanes when it comes to treating severe asthma. More intricate, and certainly requires more training and more experience, as we said earlier. I wanted to thank each and every one of you for this rich and informative exchange and discussion. And I wanted to give you each a few more minutes to summarize your thoughts. I’ll start with you, Dr Chase. Do you have any last thoughts or last words?
-
Jul 19, 2023 | 
patientcareonline.com | Raffi Tachdjian |Dareen Siri |Nicole Chase |Andrew White
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: Dr White, I’m going to give you a difficult question. How do you choose a biologic for a patient with severe asthma? Andrew White, MD: That’s tough. It’s challenging. I’ll bet if you asked the others on the panel, you’d get slightly different answers. The beauty is that we have some great options. We’ve got some awesome tools. Our other specialties are probably a bit jealous of this crazy advancement that we’ve have. It’s a good problem to have.
-
Jul 19, 2023 | 
hcplive.com | Raffi Tachdjian |Dareen Siri |Nicole Chase |Andrew White
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: Dr Chase, you’ve initiated therapy, and the patient is on this course for weeks, months, or years. Are there situations where you decide you need to switch biologics? If so, how do you determine that? How do you come to the conclusion of which therapeutic to change to? Nicole Chase, MD, FAAP, FACAAI, FAAAAI: That’s a tough question.
-
Jul 19, 2023 | 
hcplive.com | Raffi Tachdjian |Dareen Siri |Nicole Chase |Andrew White
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: Dr White, I’m going to give you a difficult question. How do you choose a biologic for a patient with severe asthma? Andrew White, MD: That’s tough. It’s challenging. I’ll bet if you asked the others on the panel, you’d get slightly different answers. The beauty is that we have some great options. We’ve got some awesome tools. Our other specialties are probably a bit jealous of this crazy advancement that we’ve have. It’s a good problem to have.
-
Jul 12, 2023 | 
hcplive.com | Raffi Tachdjian |Dareen Siri |Nicole Chase |Andrew White
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI: Dupilumab is indicated for patients aged 12 and over who have eosinophilic asthma or oral corticosteroid-dependent asthma. From the trials, it was apparent that those with high T2 [type 2] inflammatory markers tended to do better, even though the requirement is an eosinophil count of 150 cells per mm3 peripherally or greater. Dr Siri, can you deep dive into this area to guide us through some of the papers and results that made this come about? Dareen D.
